Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Effects of ciclesonide and fluticasone on cortisol secretion in patients with persistent asthma Source: Eur Respir J 2009; 33: 1277-1286 Year: 2009
Tpi 1020, a novel inhaled anti-inflammatory drug, has a different pharmacokinetic profile and lower effect on urinary free cortisol as compared to budesonide Source: Annual Congress 2009 - Translational research/biomarkers Year: 2009
The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006
Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness Source: Eur Respir J 2006; 27: 1144-1151 Year: 2006
Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology Source: Eur Respir J 2001; 17: 157-158 Year: 2001
Lung function, pharmacokinetics, and tolerability of indacaterol maleate and acetate in asthma patients Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations Source: Eur Respir J 2007; 30: 1143-1149 Year: 2007
Long-term safety of medium- and high-dose mometasone furoate/formoterol combination in persistent asthmatics: Analysis of adverse event incidence, plasma cortisol, and ocular changes Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Safety, efficacy and pharmacokinetics of inhaled TPI 1020 in smokers with asthma Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Efficacy of low dose theophylline in patient with bronchial asthma - anti-inflammatory effect Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003
Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Preclinical in vivo assessment of ciclesonide, a novel corticosteroid for the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 95s Year: 2001
The effects of addition montelukast to inhaled steroids in the regular treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001
Prolonged activity where it matters - the reversible esterfication of budesonide improves its topical anti-inflammatory efficacy and selectivity in the airways Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015
Anti-inflammatory effect of montelukast (ML) and inhaled steroids (ICS) on clinical parameters and serum levels of NO in asthmatic children Source: Eur Respir J 2003; 22: Suppl. 45, 132s Year: 2003
Dry powder inhaled ribavirin in healthy volunteers: safety, tolerability, lung and systemic pharmacokinetics Source: International Congress 2017 – From microbiology to clinical work Year: 2017